Back

Characterization of real world contemporary attr-cm patients treated with standard of care: focus on biomarkers and exercise capacity

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Arrhythmogenic right ventricular cardiomyopathy: artificial intelligence Other Nonischaemic Cardiomyopathies (Valvular, Neuromuscular, Infectious, Infiltrative, etc.) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Stefano Martano

Vito Fazzi Hospital, Lecce (Italy)

6 More presentations in this session

Presentation thumbnail
The use of high-density electroanatomic mapping catheter in detecting critical Purkinje potentials (P1-P2) in patients with left posterior fascicular VT
Associate Professor H. Koca (Adana, TR)
Abstract Slides Video
Presentation thumbnail
Early recovery during exercise testing identifies the critical window of electrocardiographic expression in Brugada syndrome
Doctor N. Pichara (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Intrinsic protection against arrhythmia in a rat model of pulmonary arterial hypertension independent of hypoxia inducible factor 2-alpha activity
Ms A. Sohi (London, GB)
Abstract Slides Video
Presentation thumbnail
When bundle branch blurs the signal: How accurate is electrocardiographic criteria for outflow tract premature ventricular complexes?
Doctor M. Osment (Columbia, US)
Abstract Slides Video
Presentation thumbnail
Artificial intelligence enhanced ECG to detect reduced LVEF: clinical significance of false positive and false negative AI-ECG classifications
Doctor R. Mistrulli (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmogenic right ventricular cardiomyopathy: artificial intelligence

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of disease-modifying treatment on functional capacity in patients with ATTR-CA: pathophysiological insights from iCPET
20 May 2023
thumbnail
Congress Presentation
Prognostic value of cardiac biomarkers in patients with transthyretin deposition cardiac amyloidosis.
29 June 2021
thumbnail
Congress Presentation
Characteristics and treatment of contemporary real-world patients with cardiac transthyretin amyloidosis: a retrospective, multicenter, observational study
11 May 2024
thumbnail
Congress Presentation
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
30 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources